|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1100 NEW YORK AVENUE, NW, #440 E |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 69674-12
|
||||||||
|
6. House ID# 357890000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Leslie Ritter |
Date | 10/19/2020 4:58:55 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 7608, H.R. 7616 - Labor, Health and Human Services, Education, Defense, Military Construction and Veterans Affairs, and Food and Drug Administration Appropriations Acts for fiscal year 2021
Defense Appropriations Act, 2021, support $20 million for the MSRP.
Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, 2021:
$471 million for the Agency for Healthcare Research and Quality (AHRQ)
$8.45 billion for the Centers for Disease Control and Prevention (CDC) inclusive of $5 million for the National Neurological Conditions Surveillance Program authorized in the 21st Century Cures Act;
$10 million for the Lifespan Respite Care Program;
Robust funding for Medicare and Medicaid and protection of Medicaids current financing structure
At least $44.7 billion for the National Institute of Health (NIH), including funds provided to the agency through the 21st Century Cures Act (P.L. 114-255) for targeted initiative;
$150 million for the Patient Centered Outcomes Research Institute (PCORI); and
$13.5 billion for the Social Security Administration
to include report language that directs a review of funding for all of the VA Centers of Excellence and enact a strategy that ensures these important programs are funded in a consistent and transparent manner and that the funding meets the scope and scale of their missions.
$3.6 billion for the Food and Drug Administration
Supporting same funding levels in Senate for these programs.
H.R. 6202 Families First Coronavirus Response Act - supplemental appropriations and health provisions related to the COVID-19 pandemic, support passage
S.3548 Coronavirus Aid, Relief, and Economic Security Act (CARES Act)- supplemental appropriations and health/economic stimulus relating to the COVID-19 pandemic, support passage.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Grant |
Couch |
|
|
|
Leslie |
Ritter |
|
|
|
Jacob |
Goodman |
|
|
|
Kimberly |
Calder |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 985, Fair Access for Safe and Timely Generics Act of 2019 (FAST Generics Act), support passage.
H.R. 2035/S. 995, Lifespan Respite Care Reauthorization Act, support reauthorization
H.R. 3208/ S.1755 - Real Emergency Access for Aging and Disability Inclusion for Disasters Act, support passage
H.R. 2781 - Empower for Health Act of 2019, support passage
H.R. 2296/S.1391 - FAIR Drug Pricing Act of 2019, support passage
H.R. 3630 - No Surprises Act, support passage
H.R. 1010, To provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect, support passage.
H.R. 986, The Protecting Americans with Preexisting Conditions Act of 2019, support passage.
H.R.1386, Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act of 2019, support passage.
H.R. 2408, the Ensuring Access to Quality Complex Rehabilitation technology Act, support passage.
H.R 3 - Lower Drug Costs Now Act of 2019, support passage
H.R. 19 - Lower Costs, More Cures Act of 2019, support passage
H.R. 2387, the Stop The Overuse of Petitions and Get Affordable Medicines to Enter Soon (STOP GAMES) Act of 2019, support passage
H.R. 6417, Protecting Cures Act of 2020, support passage
H.R. 5800, Ban Surprise Billing Act, support passage
H.R. 1595, Secure and Fair Enforcement Banking Act (SAFE Banking Act), support passage
S. 1935, Family Coverage Act, support passage.
S.1556, No Junk Plans Act, support passage.
S.475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2019 (RX Cap Act), support passage
S. 637, Combatting Unreasonable Rises and Excessively High Drug Prices Act (CURE High Drug Prices Act), support passage
S.366, Forcing Limits on Abusive and Tumultuous Prices (FLAT Prices) Act, support passage
S. 63, Preserve Access to Affordable Generics and Biosimilars Act, support passage
S. 659, Biologic Patent Transparency Act, support passage
S.1895 - Lower Health Care Costs Act, support passage
S. 2543 - Prescription Drug Price Reduction Act of 2019 - support passage
S. 1801, Low Cost Generics Act of 2019, support passage
H.R. 1425 Patient Protection and Affordable Care Enhancement Act, support
H.R. 6514, Worker Health Coverage Protection Act, Support
H.R. 3832, S. 1257, Legacy IRA Act, Support
H.R. 6408 - Save the Organizations that Serve America Act
S.3544/H.R.6305 - Coronavirus Relief for Seniors and People with Disabilities Act of 2020, support
S. 3815, RESTART Act, Oppose
S. 3833/H.R. 7010/H.R.6886, Paycheck Protection Program Flexibility Act of 2020, Support
S. 4032/H.R. 7324, Universal Giving Pandemic Response Act. Support passage
H.R. 6892-Help Charities Protect Communities Act, Support
- S.Amdt. 1566 to the CARES Act, Charitable Giving
oAmendment Increases the $300 limit on the charitable giving deduction to one-third of the standard deduction ($4,000 for an individual filer/$8,000 for married joint filers) for the remainder of 2020. Support.
H.R. 7663-Protecting Access to Post-COVID-19 Telehealth Act, support passage
H.R. 6644/S. 3741 - Health Care At Home Act, support passage
H.R. 7391- the Protect Telehealth Access Act, support passage
S. 3998- the Enhancing Preparedness Through Telehealth Act, support passage
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kimberly |
Calder |
|
|
|
Leslie |
Ritter |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3215/ S. 1754 - Disaster Relief Medicaid Act, support passage
H.R. 7647
H.R. 2293, the Protecting Access to Wheelchairs Act, support passage
H.R. 3107, Improving Seniors Timely Access to Care Act of 2019, support passage
S. 1223, the Protecting Beneficiary Access to Complex Rehab Technology Act, support passage
S. 1280/HR 2477 - Beneficiary Enrollment Notification and Eligibility Simplification (BENES) Act, support passage
S. 691 - Medicare Extra Rx Help Act- support passage
S. 2543 - Prescription Drug Price Reduction Act of 2019 - support passage
oMenendez - Lankford- Cardin-Daines Amendment 1
Incentivizing Generic and Biosimilar Use in Medicare Part D - support adoption
oMenendez -Lankford - Cardin --Daines Amendment 2
Incentivizing Generic Use in Medicare Part D, support adoption
S.2911, the Seniors Prescription Drug Relief Act of 2019, support passage.
S.4468, COVID-19 Treatment Coverage Act, support passage
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kimberly |
Calder |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
|
Leslie |
Ritter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 7308/S.4286 Research Investment to Spark the Economy Act (RISE) Act, support passage
oSupport Markey Amendment in the Nature of a Substitute
to add provisions allowing for $2 billion in funding for non-profit research stalled by the COVID-19 pandemic and $1 billion in funding to aid in clinical trial sites.
S.2400/ H.R. 4322 - Expanding Cannabis Research and Information Act, support passage
H.R. 3439 - Reauthorization of the Patient Centered Outcomes Research Institute, support reauthorization.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Grant |
Couch |
|
|
|
Leslie |
Ritter |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
N/A
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
Signed on to letter dated 4.16.20 to HHS Secretary Azar and Office of Civil Rights (OCR) Director Severino urging further executive action and additional guidance to assure any care rationing plans fully comply with federal anti-discrimination laws.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
No foreign interests.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |